Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding by Ballester-Clau, Raquel et al.
D
ow
nloaded
from
https://journals.lw
w
.com
/eurojgh
by
B
hD
M
f5eP
H
K
av1zE
oum
1tQ
fN
4a+kJLhE
ZgbsIH
o4X
M
i0hC
yw
C
X
1A
W
nY
Q
p/IlQ
rH
D
3tIQ
5gQ
C
Ieyw
Y
tA
E
+U
hcpnR
hw
B
Lgym
X
ji7K
qxhzK
K
Tw
D
E
A
K
6t7JV
G
S
A
==
on
02/18/2019
Downloadedfromhttps://journals.lww.com/eurojghbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3tIQ5gQCIeywYtAE+UhcpnRhwBLgymXji7KqxhzKKTwDEAK6t7JVGSA==on02/18/2019
Clinical experience with ferric carboxymaltose in the
management of anemia in acute gastrointestinal
bleeding
Raquel Ballester-Claua,b, Gisela Torres Vicentea,b, Tania Voltà-Pardoa, Laura López-Barrosoa,
Mercedes Cucala-Ramosc, Josep M. Reñé-Espineta,b and Montse Planella de Rubinata,b
Objective The aim of this study was to assess the efﬁcacy and safety of intravenous ferric carboxymaltose (FCM) following
hospitalization for acute gastrointestinal bleeding (AGIB) in the context of a restrictive transfusion strategy.
Patients and methods A retrospective single-center study analyzed patients with AGIB (excluding AGIB secondary to portal
hypertension) administered a single FCM dose with or without blood transfusion.
Results Eighty-six episodes in 84 patients were analyzed. Seventy-nine patients had upper AGIB. Nineteen episodes were
associated with hemodynamic instability. FCM was administered during hospitalization as a single dose of 1000mg iron in 84/86
episodes and as a single dose of 500mg iron in two episodes, with blood transfusion in 60/86 (69.8%) episodes. The mean
hemoglobin (Hb) was 9.0 g/dl at admission, 7.6 g/dl at the lowest in-hospital value, 9.4 g/dl at discharge, and 12.7 g/dl at follow-
up (mean: 55 days postdischarge) (P<0.001 for follow-up vs. all other timepoints). The lowest mean in-hospital Hb value was 7.2
and 8.8 g/dl, respectively, in patients with transfusion+ FCM versus FCM alone; the mean Hb was 12.4 versus 13.7 g/dl at follow-
up. In patients administered FCM alone, the mean Hb at follow-up in the subpopulations aged older than or equal to 75 years
(n= 33), Charlson comorbidity index of at least 3 (n= 48), and Hb of up to 10 g/dl at admission (n=47) were 12.6, 13.1, and
13.3 g/dl, respectively. No adverse effects were detected.
Conclusion Treatment with FCM for AGIB is associated with a good erythropoietic response and anemia correction after
hospitalization, even in severe episodes or when transfusion is needed. FCM is safe and well tolerated, and may support a
restrictive transfusion policy. Eur J Gastroenterol Hepatol 31:116–122
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
Introduction
Acute gastrointestinal bleeding (AGIB) is a common cause of
hospitalization. Recent prospective studies have estimated
the incidence to be 87 cases per 100 000 population for
acute upper or lower gastrointestinal (GI) bleeding [1,2], and
up to 76 patients are hospitalized per 100 000 population as
a result [3,4]. Mortality is high, with estimates typically in
the range 3–14% [5–7].
The immediate clinical priority is to stabilize the
patient, stop the hemorrhage, and where necessary use
blood transfusion to correct severe anemia [8]. Blood
transfusion is widely used in cases of AGIB, but it is
increasingly being recognized that overtransfusion should
be avoided to improve survival rates [9]. Transfusion
increases the risk of nosocomial infection and is associated
with increased mortality in high-risk hospitalized patients
[10], as well as incurring substantial ﬁnancial costs.
Moreover, it is associated with an increased risk for
rebleeding and higher mortality [9,11]. Restricted use of
blood transfusion, whereby it is administered only to
patients with very low hemoglobin (Hb) levels, has become
the standard of care in many types of AGIB [12]. European
and US guidelines recommend a restrictive transfusion
strategy that targets a Hb level between 7and 9 g/dl or
higher Hb target levels if the patient has intravascular
volume depletion or signiﬁcant comorbidity such as
ischemic cardiovascular disease [13,14]. A recent meta-
analysis of ﬁve randomized-controlled trials showed that
compared with a liberal transfusion strategy, restrictive
transfusion is associated with a signiﬁcant reduction in all-
cause mortality [15].
Longer-term restoration of normal Hb levels after
AGIB, however, is often neglected. Current recommenda-
tions do not address the use of iron supplementation [13,
14] despite the fact that anemia affects 50–80% of patients
discharged after AGIB [16–18] and iron deﬁciency has
been documented in ~ 50% of patients at discharge [19].
Management of anemia is clearly important in this
aDepartment of Gastroenterology, Arnau de Vilanova University Hospital, bInstitute
for Biomedical Research in Lleida Dr. Pifarré Foundation, IRB Lleida, Lleida and
cMedical Department, Vifor Pharma España S.L., Barcelona, Spain
Correspondence to Raquel Ballester-Clau, MD, Department of Gastroenterology,
Hospital Universitari Arnau de Vilanova Av, Rovira Roure no. 80, 25198 Lleida,
Spain
Tel: + 34 973 705 342; fax: + 34 973 705 194;
e-mail: rballester.lleida.ics@gencat.cat
Received 30 May 2018 Accepted 15 September 2018
This is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-
ND), where it is permissible to download and share the work provided it is properly
cited. The work cannot be changed in any way or used commercially without
permission from the journal.
European Journal of Gastroenterology & Hepatology 2019, 31:116–122
Keywords: acute gastrointestinal bleeding, anemia, ferric carboxymaltose,
hemoglobin, intravenous iron
’Original article
0954-691X Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. DOI: 10.1097/MEG.0000000000001282 116
population, but a survey conducted in Canada in 2016
found that fewer than 15% of clinicians prescribe iron
therapy in patients who are anemic after AGIB, and that
oral iron is the selected mode of administration in 80% of
treated patients [20]. Another survey, in Denmark,
reported that only 13% of discharged anemic patients are
administered oral iron supplementation after AGIB, with
none administered intravenous (i.v.) iron [16,21].
Some experts suggest that high-dose i.v. iron formula-
tions would be logical after AGIB because iron replenish-
ment is rapid and treatment is well tolerated, and i.v.
therapy avoids the risk of poor compliance that can occur
with oral iron treatment [22]. In recent years, new i.v. iron
preparations have been developed that allow larger doses
of iron to be administered in a single dose, reducing the
cumulative risk for infusion reactions as well as improving
convenience for physicians and patients [23]. One of these
is ferric carboxymaltose (FCM), an i.v. iron preparation in
which a nondextran, stable carbohydrate shell facilitates
the release of iron in a controlled manner [24]. FCM can
be infused in a single dose of up to 1000mg iron over
15min. A network meta-analysis of six randomized-
controlled trials across various indications of chronic
kidney disease [25], inﬂammatory bowel disease [26],
postpartum anemia [27,28], heavy uterine bleeding [29],
and fatigue [30] has shown that FCM improves levels of
serum ferritin and transferrin saturation, and corrects Hb
levels, more rapidly than oral iron, and it is well tolerated
[31]. It has a low risk of hypersensitivity reactions [24].
There are no studies that assess the efﬁcacy and safety
of i.v. iron treatment in patients with AGIB. A retro-
spective analysis was carried out to assess the efﬁcacy and
safety of i.v. FCM following hospital admission for AGIB
at a center where a restrictive blood transfusion policy is
followed.
Patients and methods
This was a retrospective analysis of patients admitted with
AGIB to the Gastroenterology Department of the Hospital
Universitari Arnau de Vilanova, Lleida, Spain, in whom
treatment included FCM therapy. The center routinely
treats anemia in hospitalized patients with FCM (Ferinject,
Vitor Pharma España S.L., Barcelona, Spain). The study
included all eligible patients admitted from October 2012
to December 2015. Patients for inclusion in the current
analysis were identiﬁed by searching the pharmacy records
for all patients who received FCM during the study period,
and then each clinical history was checked manually.
Patients with AGIB because of portal hypertension were
excluded. No other exclusion criteria were applied.
AGIB was deﬁned as externalized bleeding (hematem-
esis, melena, or rectal bleeding) with/without hemody-
namic instability [systolic blood pressure< 100mmHg
with/without tachycardia (>100 bpm)].
Blood transfusion was administered on admission or
during hospitalization if the Hb level was lower than 7 g/
dl, or at higher levels of Hb if comorbidities or hemody-
namic instability were present (at the physician’s discre-
tion). The decision on whether or not to administer blood
transfusion was not inﬂuenced by the patient’s iron status
on the basis of mean corpuscular hemoglobin or mean
corpuscular volume measurements.
FCM was administered as a single dose of 1000mg iron
over 15min during hospitalization after the patient had
been stabilized. A follow-up visit took place ~ 2 months
after discharge, and included blood sampling for the
determination of Hb level [32].
The following information was obtained from patients’
medical records: demographic and clinical data, presentation
and severity of AGIB (symptoms, hemodynamic instability,
Charlson comorbidity index [33], Glasgow–Blatchford index
score [34]), endoscopic features (cause of hemorrhage,
endoscopic treatment, and Rockall index score [32]), medical
treatment (number of blood transfusion units, total dose of
FCM), Hb level (at hospital admission, the lowest value
during hospital stay, at discharge, and at follow-up), and the
duration of hospital stay. The mean change in Hb from the
lowest value during hospitalization to (a) the value at hospital
discharge and (b) the follow-up visit was calculated. Changes
in Hb to both timepoints were also analyzed in the following
subgroups: (i) patients aged younger than 75 or older than or
equal to 75 years at admission (ii) patients with a Charlson
comorbidity index less than 3 or at least 3 and (iii) patients
with Hb above 10 g/dl or up to 10 g/dl at admission to
hospital. These subgroups were considered to be high-risk
populations: older age is associated with a higher risk of
mortality; comorbidity as measured by the Charlson comor-
bidity index incurs a higher risk of mortality; and the Hb level
indicates the severity of the GI bleeding (Hb≤10 g/dl at
hospital admission predicts iron deﬁciency anemia at 30 days
after AGIB [18]).
Values are reported as n (%) for categorical variables
and as mean ± SD values for continuous variables. Values
were compared between subpopulations using the χ2-test,
Student’s t-test, or paired t-test, as appropriate.
Study conduct
The study was carried out in accordance with the
Declaration of Helsinki and Good Clinical Practice
Guidelines. The study protocol was approved by the
Hospital Ethics Committee and Health Authorities (pro-
tocol number: RBC-HE-2018-01). All authors approved
the procedures for data analysis and approved the ﬁnal
version of the manuscript for publication.
Results
Study population
In total, 84 patients were admitted with AGIB and treated
with FCM during the study period. Seventy-nine (94.0%)
patients had upper GI bleeding and ﬁve patients had lower
GI bleeding (6%). The majority of patients (58/84) were
male. The population had a high rate of comorbidities,
with 51 (60.7%) patients having a Charlson comorbidity
index score of at least 3. Thirteen (15.5%) patients had
experienced previous AGIB (Table 1). Overall, only four
patients had previously received antiaGGreGant medica-
tion, and Hb levels at admission, discharge, and follow-up
in these individuals were similar to the rest of the study
population. No other patient had been treated with
antiaGGreGant therapy or nonsteroidal anti-inﬂammatory
drugs. Two patients were admitted twice for AGIB bleed-
ing and received FCM and blood transfusion on both
occasions, such that a total of 86 episodes were analyzed.
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On admission, the majority presented with melenas [66/86
(76.7%)] and 21 (23.5%) patients presented with hematem-
esis. Approximately one in ﬁve [19/86 (22.1%)] had hemo-
dynamic instability conﬁrmed at hospital admission. Multiple
presentations were common, with 17 patients having melena
and symptoms of hemodynamic instability and nine having
melena and hematemesis. In six (7%) patients, the initial
symptom was weakness, presenting GI bleeding at admission.
The most common causes of hemorrhage were duodenal and
gastric ulceration (Table 2).
The mean±SD levels of mean corpuscular hemoglobin
(29.8±3.38 pg) and mean corpuscular volume (90.1±7.59 ﬂ)
across the study population were within the normal range at
admission.
Treatment and hospital stay
The total dose of FCM was 1000mg iron in 84/86
(96.5%) episodes, administered as a single infusion. In two
further patients, who weighed less than 50 kg, a total dose
of only 500mg iron was calculated to be necessary. One
patient was administered a dose of 1000mg iron and also
received an additional FCM dose of 500mg iron after a
low Hb value was recorded at the follow-up visit.
One or more blood transfusion was administered for
60/86 (69.8%) episodes using a mean of 3.0 ±1.7 units of
blood (Table 2). No oral iron or vitamin supplements were
administered to any patient.
The mean hospital stay associated with AGIB was
7.9 ±5.0 days. Patients requiring transfusion remained in
hospital a mean of 8.2± 5.2 days compared with 7.2 ±4.6
for those without transfusion (P<0.0001).
The postdischarge follow-up visit at the hospital out-
patient clinic took place at a mean of 60.9 ±39.6 days after
leaving hospital.
Safety events
There were no severe adverse events associated with FCM
administration in any patient during hospitalization, and
none were reported at the follow-up visit.
One patient experienced a rebleeding episode in the
upper GI tract because of cameron ulcers at 3.5 months
after hospital discharge. Two patients died because of
underlying pathologies: one death occurred at 1 month
after hospital discharge as a result of previously diagnosed
pancreatic neoplasia and one death occurred 3 months
after discharge because of complications related to GI
bleeding in a patient with multiple comorbidities.
Hemoglobin response
In the total study cohort, the mean Hb at the time of hospital
admission was 9.0±2.2 g/dl, decreasing to 7.6±1.3 g/dl at
Table 1. Demographic and clinical characteristics of patients admitted
for acute gastrointestinal bleeding and treated with ferric
carboxymaltose
All patients
(N=84)a
Transfusion+ FCM
(N=58) FCM (N=26)
Sex [n (%)]b
Male 58 (69.0) 39 (67.2) 19 (73.1)
Female 26 (31.0) 19 (32.8) 7 (26.9)
Age (years)c
(mean ±SD)
68.0 ± 16.9 70.0 ± 16.8 63.2 ±16.5
Charlson index [n (%)]b
Score 0 5 (6.6) 2 (3.8) 3 (13.0)
Score 1–2 20 (26.3) 13 (24.5) 7 (30.5)
Score 3–4 27 (35.5) 17 (32.1) 10 (43.5)
Score ≥5 24 (31.6) 21 (39.6) 3 (13.0)
Previous acute
bleeding [n (%)]b
13 (15.5) 7 (12.1) 3 (11.5)
FCM, ferric carboxymaltose; Hb, hemoglobin.
aTwo of these 84 patients were admitted twice. Among patients with Charlson
index score ≥3; Hb data were missing in three patients (two transfusion +FCM,
one FCM).
No statistically signiﬁcant differences.
bχ2-Test.
cStudent’s t-test.
Table 2. Characteristics of acute gastrointestinal bleeding episodes in
patients treated with ferric carboxymaltose
All
episodes
(N=86)a
Transfusion+ FCM
(N=60)
FCM
(N=26) P
Clinical presentation [n (%)]b,c
Hematemesis 21 (23.5) 19 (31.7) 14 (53.8) 0.020
Melena 66 (76.7) 50 (83.3) 16 (61.5) 0.047
Symptoms of
hemodynamic
instabilityd
22 (25.6) 16 (26.7) 6 (23.1) NS
Hemodynamic instability
conﬁrmed on
admission [n (%)]
19 (22.1) 15 (25.0) 4 (15.4) NS
Hb at admission (g/dl)
Mean ±SDc 9.0 ±2.2 8.2 ±2.0 10.8 ±1.4 <0.05
Patients with ≤10
[n (%)]f
47 (54.7) 40 (66.7) 7 (26.9) <0.001
Lowest in-hospital Hb (g/dl)
Mean ±SDf 7.6 ± 1.3 7.2 ±1.3 8.8 ± 0.6 <0.001
GI bleeding before
hospital admission
[n (%)]c
81 (94.2) 57 (95.0) 24 (92.3) NS
Glasgow–Blatchford
index (mean ±SD)f
10.9 ±2.7 11.8 ± 2.4 8.8 ± 2.3 <0.001
Rockall index
(mean ±SD)f
4.2 ±1.7 4.5 ±1.8 3.5 ± 1.2 0.010
Cause of hemorrhage [n (%)]c
Duodenal ulcer 31 (36.0) 19 (31.7) 12 (46.2) NS
Gastric ulcer 25 (29.0) 20 (33.3) 5 (19.2) NS
Gastritis/erosions 8 (9.3) 4 (6.7) 4 (15.4) NS
Duodenitis 7 (8.2) 7 (11.7) 0 NS
Hemorrhoids 2 (2.5) 2 (3.3) 0 NS
Diverticulitis 2 (2.5) 2 (3.3) 0 NS
Transfusionf
Number of
transfusions
60 60 −
Number of blood units
(mean ±SD)
3.0 ±1.7 3.0 ±1.7 −
Pretransfusion Hb
(mean ±SD) (g/dl)
7.1 ± 1.4 7.1 ±1.4 −
Total dose of FCM administered [n (%)]c (mg)
500 2 (2.3) 1 (1.7) 1 (3.8) NS
1000g 84 (96.5) 60 (100) 23 (88.5)
Duration of hospital stay (days) (all patients)f
Mean ±SD 7.9 ± 5.0 8.2 ±5.2 7.2 ±4.6 <0.0001
Median (range) 7 (1–41) 7 (1–41) 6 (1–26)
AGIB, acute gastrointestinal bleeding; FCM, ferric carboxymaltose; GI, gastro-
intestinal; Hb, hemoglobin.
aIncluding two patients who were admitted twice for two different AGIB episodes.
bMultiple presentations were possible: melena+symptoms of hemodynamic
instability 17, hematemesis+symptoms of hemodynamic instability 1; hematemesis-
+melena 9, melena+symptoms of hemodynamic instability+ hematemesis 1.
cχ2-Test.
dSyncope and/or dizziness.
eDeﬁned as systolic blood pressure <100mmHg with/without tachycardia, and signs
of tissue hypoperfusion.
fStudent’s t-test.
gOne patient in the FCM group received an additional 500mg iron dose after the
follow-up visit.
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the lowest point during the hospital stay and before trans-
fusion or administration of FCM. By the time of discharge,
the mean Hb had increased to 9.4±1.1 g/dl (P<0.001 vs.
the lowest in-hospital Hb value). The increase in the mean
Hb during the hospital stay was largely accounted for by the
group who received one or more blood transfusion (Fig. 1).
The lowest mean Hb level during hospitalization was lower
in the group administered blood transfusion plus FCM
versus FCM alone (7.2±1.3 vs. 8.8±0.6 g/dl, P<0.001).
By the time of discharge, both groups had a similar
mean Hb level (9.4 ±1.2 and 9.3 ± 0.8 g/dl, respectively)
(Fig. 1). At the postdischarge follow-up visit, the mean Hb
was 12.7 ± 2.4 g/dl (P< 0.001 vs. Hb at admission and vs.
the lowest in-hospital Hb value).
The mean Hb was in the normal range both in the
patients administered transfusion and FCM (12.4 ±2.5 g/
dl) or FCM alone (13.7 ±1.8 g/dl) (Fig. 1). The Hb level
was up to 10 g/dl at follow-up in 5/40 patients adminis-
tered FCM plus transfusion FCM (13.9%) compared with
0/7 patients administered FCM alone. The increase in Hb
from admission and from the lowest in-hospital Hb level
to follow-up was signiﬁcant with FCM with or without
transfusion (P<0.001 in all cases) (Fig. 1). At follow-up,
Hb levels normalized (Hb≥12 g/dl in women and ≥ 13 g/
dl in men) in 60.0% of patients administered FCM plus
transfusion versus 75.0% given FCM alone.
Hemoglobin response in at-risk patient subpopulations
Patients older than or equal to 75 years who received FCM
plus transfusion [28/33 (84.8%)] had a mean Hb at
admission of 8.0 versus 11.1 g/dl for those administered
FCM alone (P= 0.001); Hb was 9.7 vs. 9.6 g/dl at dis-
charge (NS) and 12.7 vs. 12.6 g/dl at follow-up (NS).
Patients treated with FCM and transfusion who had a
Charlson comorbidity index of at least 3 [36/46 (78.3%)
among patients for whom Hb data were available] had a
mean Hb at admission of 7.9 versus 11.2 g/dl for FCM
plus transfusion versus FCM alone (P< 0.001); the mean
Hb was 9.6 versus 9.7 g/dl at discharge (NS) and 12.0
versus 13.1 g/dl at follow-up (NS). Finally, for patients
with Hb of up to 10 g/dl at admission, the mean Hb at
admission in the group administered FCM plus transfusion
[40/47 (85.1%)] was 7.3 versus 9.1 g/dl in the FCM group
(P= 0.004), 9.5 versus 8.9 g/dl at discharge (NS), and 12.6
versus 13.3 g/dl at follow-up (NS).
The mean increase in Hb from the lowest in-hospital
Hb value to the point of discharge and to the follow-up
visit was analyzed overall (Fig. 2a), in older patients
[≥75 years (n=33)] (Fig. 2b), in patients with the highest
morbidity scores [Charlson index≥3 (n=48)] (Fig. 2c),
and in patients with moderate or severe anemia
[Hb≤ 10 g/dl (n= 47)] at admission (Fig. 2d). These sub-
groups each showed a larger mean increase in Hb from
the lowest in-hospital Hb value to the value at discharge
than in their lower-risk counterparts: 2.1 ±1.7 versus
1.4 ±1.5 g/dl for patients aged older than or equal to
75 years versus younger than 75 years (P<0.001);
1.9 ±1.6 versus 1.3 ± 1.5 g/dl for patients with Charlson
index of at least 3 versus less than 3 (P< 0.001); and
2.0 ±1.7 versus 1.0 ±1.3 g/dl for patients with Hb of up to
10 g/dl at admission versus more than 10 g/dl (P<0.001).
In each of these subpopulations, the change in the mean
Hb level to the follow-up visit was higher in the patients
administered blood transfusion in addition to FCM versus
FCM alone (Fig. 2b–d). However, even in patients admi-
nistered only FCM, the mean Hb level was within the
normal range or close to normal by the follow-up visit:
12.6 ±2.3 g/dl in patients aged older than or equal to
75 years, 13.1 ±2.0 g/dl in patients with Charlson index of
at least 3, and 13.3 ±1.3 g/dl in patients with Hb of up to
10 g/dl at admission.
Discussion
International recommendations advise that transfusion
should be restricted to cases of severe anemia (< 7 g/dl)
in patients with AGIB, except under speciﬁc circumstances
[13,14]. At our center, use of blood transfusion
was restricted to patients with the lowest Hb levels (mean
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7.2 g/dl at the lowest in-hospital measurement in the cur-
rent cohort), a strategy shown to improve survival
rates [9].
The rapid rate of erythropoiesis that is required after
acute blood loss demands an adequate supply of iron.
Well-designed trials of i.v. iron therapy in this setting are
rare. A randomized comparative trial by Ferrer-Barceló
et al. [35], which compared FCM versus oral iron in 55
patients with anemia after AGIB, showed a faster Hb
response and normalization of transferrin saturation by
day 7 with FCM versus oral iron, with fewer adverse
events and improved tolerance in the FCM cohort. A
double-blind, placebo-controlled study has been carried
out in which 97 patients with nonvariceal upper GI
hemorrhage were randomized to i.v. FCM, oral iron, or
placebo [36]. The erythropoietic response was similar with
either FCM or oral iron, but ferritin levels increased more
rapidly with FCM (mean: 874 vs 149 μg/l at week 4). In
our study, a single FCM dose was adequate to manage
anemia without blood transfusion in 30% of patients. The
mean Hb level at follow-up was either normal or close to
normal both in patients administered transfusion and
FCM and in those managed with FCM alone, with 60% of
transfused patients and 75% of those receiving only FCM
achieving normal Hb levels.
Three patient subpopulations considered to be at risk
for poor outcomes were examined separately. The ﬁrst
group included older patients (≥75 years). Older age is a
known risk factor for anemia, often associated with iron
deﬁciency or renal insufﬁciency [37], and has been
reported to increase the risk of anemia after AGIB [18].
Older patients may also be more likely to experience
rebleeding and in-hospital mortality than younger patients
[6,38,39]. The second group included patients with mul-
tiple comorbidities (Charlson comorbidity index≥ 3).
Highly comorbid patients frequently have primary or
secondary renal dysfunction, reducing erythropoietin
production and restricting erythropoiesis, with an asso-
ciated increase in predicted health costs [40] and are at
greater risk for death following AGIB [41]. The last group
was patients with moderate or severe anemia at admission
(≤10 g/dl). Low Hb (≤10 g/dl) at baseline is, as one would
expect, predictive of subsequent anemia [18]. Hb less than
10 g/dl has been shown to be an independent predictor for
rebleeding, need for intervention, or death following AGIB
[42]. In these three groups, FCM alone achieved a mean
Hb increase in the range 3.0–4.6 g/dl, and the mean Hb at
follow-up was normal or close to normal.
According to our results, 15% of patients older than or
equal to 75 years, 25% of patients with Charlson
comorbidity index of at least 3, and 15% of patients with
Hb of up to 10 g/dl at admission were managed only with
FCM, achieving a signiﬁcant increase in Hb and normal-
izing or almost normalizing Hb values at follow-up with a
mean Hb of 12.6 g/dl in older than or equal to 75 years;
13.1 g/dl in Charlson index of at least 3; and 13.2 g/dl in
those with Hb of up to 10 g/dl on admission.
These are encouraging ﬁndings, given the importance of
achieving a sustained hematopoietic response and avoiding
transfusion in these vulnerable patient groups.
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In our series of 84 patients (86 AGIB episodes), no
clinical adverse events were observed following FCM
treatment. A meta-analysis of 11 randomized trials and
three cohort studies of FCM at a dose of up to 1000mg
iron, in a range of clinical settings, has concluded that
FCM is associated with fewer GI adverse events compared
with oral iron, and that there are no FCM-related safety
concerns [43]. Another recent meta-analysis, which com-
pared different i.v. iron preparations, observed that FCM
tends to be better tolerated than iron sucrose or iron iso-
maltoside [44].
This analysis reﬂects routine clinical practice, including
the typical range of patients who present with AGIB. The
only exclusion was patients with bleeding secondary to
portal hypertension, which represents a different condition
and requires different management. The major limitation
of the study is the absence of a control group receiving
only transfusions. In this group of patients with a high rate
of comorbidities and low baseline Hb, routine practice at
our center mandates i.v. iron to ensure rapid repletion of
iron stores after acute hemorrhage. Second, as a retro-
spective analysis, transfusion decisions were made by the
responsible clinician on the basis of the center’s standard
restrictive transfusion policy. Third, data on Hb levels
after hospital discharge were obtained at routine out-
patient follow-up visits and the timing varied between
patients. However, as production of new red cells takes
~ 25 days [45] and the mean interval between hospital
discharge and the follow-up visit was 60 days, follow-up
data are likely to have reﬂected the peak erythropoietic
response to iron repletion by FCM. Finally, markers of
iron status were only available infrequently in the patient
records, reﬂecting the retrospective nature of the study.
Thus, although the high rate of Hb normalization points to
effective iron replenishment, this cannot be conﬁrmed
directly. However, the randomized study by Ferrer-Barceló
et al. [35], which compared FCM versus oral iron in AGIB
patients, reported signiﬁcantly greater repletion of iron
deposits under FCM versus oral iron at the end of the
6-week study (75 vs. 26% P=0.0007).
Conclusion
Treatment with a single dose of FCM in patients with
AGIB as part of a restrictive transfusion policy is asso-
ciated with a good erythropoietic response and recovery
from anemia after the immediate period of hospitalization.
Although it is not the recommended dose to replenish iron
deposits, a good erythropoietic response to a single infu-
sion of FCM 1000mg was observed in at-risk subgroups
including patients aged older than or equal to 75 years,
those with high comorbidity, and patients with moderate
to severe anemia. Almost normal mean Hb values were
achieved in these three groups, in whom improving Hb
levels may be particularly important. FCM therapy was
safe and well tolerated in this population, which included a
high proportion of elderly patients and patients with
multiple comorbidities, with no severe adverse events.
Providing effective iron repletion during hospitalization
through i.v. FCM therapy can help to avoid transfusion
even in high-risk patients and also avoid the longer-term
anemia so frequently observed after AGIB.
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